FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238514467> ?p ?o ?g. }

• W4238514467 endingPage "e15753" @default.
• W4238514467 startingPage "e15753" @default.
• W4238514467 abstract "e15753 Background: Significant progress has been made in the understanding of the genomic landscape of PDAC, but the clinical utility of these data remains uncertain. Methods: As part of the BC Cancer Personalized Oncogenomics (POG) and PanGen studies (NCT02155621, NCT02869802), whole genome analysis and transcriptome sequencing were performed on fresh biopsy and blood sample from 48 mPDAC patients. Genomic findings informed therapy choices including potential eligibility for the CCTG PM.1 molecular basket trial (NCT03297606). Results: Cohort consists of 54.1% male, average age 57.6, 34/48 had ≥2 lines of treatment. 37/48 biopsies were from liver and 27/48 were collected pre-treatment. 8/48 (16.6%) patients had aberrations with strong evidence of clinical actionability. These include 2 germline BRCA2, 1 germline BRCA1, 1 somatic XRCC2 homozygous deletion with strong COSMIC signature 3, all predictive of platinum sensitivity. Patients with XRCC2 deletion and BRCA1 had over 2 years on FOLFIRINOX. Fusions affecting the NRG1 gene were identified in 3/4 patients with KRAS wildtype tumours, which may confer ERRB inhibitor sensitivity. 2/3 NRG1 fusion patients have thus far been treated with the ERBB inhibitor afatinib with radiographic responses noted in both patients. One patient had mismatch repair deficiency, and a high mutational burden, suggestive of immune checkpoint inhibitor sensitivity. Other possible actionable mutations include CCTG PM.1 trial potential eligibility: 4/48 with high homologous recombination defects and 1 germline ATM mutation loss (PARP inhibitor arm), 1/47 ERBB2 amplification (anti-HER2 arm), 2/47 high expression of FGFR1 (Sunitinib arm) and 1/47 with high FLT4 and IGF1R expression (Axitinib arm). Conclusions: More routine use of comprehensive genomic analysis should be considered in mPDAC given finding of high degree of actionability. Importantly, a significant proportion (16.6%) had findings with strong evidence of clinical impact." @default.
• W4238514467 created "2022-05-12" @default.
• W4238514467 creator A5001731680 @default.
• W4238514467 creator A5015015784 @default.
• W4238514467 creator A5036473360 @default.
• W4238514467 creator A5040463490 @default.
• W4238514467 creator A5043250503 @default.
• W4238514467 creator A5044366354 @default.
• W4238514467 creator A5054009874 @default.
• W4238514467 creator A5062939544 @default.
• W4238514467 creator A5068084223 @default.
• W4238514467 creator A5068644454 @default.
• W4238514467 creator A5069667659 @default.
• W4238514467 creator A5070061359 @default.
• W4238514467 creator A5070331492 @default.
• W4238514467 creator A5081831776 @default.
• W4238514467 creator A5084671659 @default.
• W4238514467 creator A5085439016 @default.
• W4238514467 creator A5088331751 @default.
• W4238514467 creator A5089913686 @default.
• W4238514467 creator A5091086534 @default.
• W4238514467 creator A5091747658 @default.
• W4238514467 date "2019-05-20" @default.
• W4238514467 modified "2023-10-12" @default.
• W4238514467 title "Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations." @default.
• W4238514467 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15753" @default.
• W4238514467 hasPublicationYear "2019" @default.
• W4238514467 type Work @default.
• W4238514467 citedByCount "1" @default.
• W4238514467 countsByYear W42385144672021 @default.
• W4238514467 crossrefType "journal-article" @default.
• W4238514467 hasAuthorship W4238514467A5001731680 @default.
• W4238514467 hasAuthorship W4238514467A5015015784 @default.
• W4238514467 hasAuthorship W4238514467A5036473360 @default.
• W4238514467 hasAuthorship W4238514467A5040463490 @default.
• W4238514467 hasAuthorship W4238514467A5043250503 @default.
• W4238514467 hasAuthorship W4238514467A5044366354 @default.
• W4238514467 hasAuthorship W4238514467A5054009874 @default.
• W4238514467 hasAuthorship W4238514467A5062939544 @default.
• W4238514467 hasAuthorship W4238514467A5068084223 @default.
• W4238514467 hasAuthorship W4238514467A5068644454 @default.
• W4238514467 hasAuthorship W4238514467A5069667659 @default.
• W4238514467 hasAuthorship W4238514467A5070061359 @default.
• W4238514467 hasAuthorship W4238514467A5070331492 @default.
• W4238514467 hasAuthorship W4238514467A5081831776 @default.
• W4238514467 hasAuthorship W4238514467A5084671659 @default.
• W4238514467 hasAuthorship W4238514467A5085439016 @default.
• W4238514467 hasAuthorship W4238514467A5088331751 @default.
• W4238514467 hasAuthorship W4238514467A5089913686 @default.
• W4238514467 hasAuthorship W4238514467A5091086534 @default.
• W4238514467 hasAuthorship W4238514467A5091747658 @default.
• W4238514467 hasConcept C104317684 @default.
• W4238514467 hasConcept C121608353 @default.
• W4238514467 hasConcept C126322002 @default.
• W4238514467 hasConcept C13514818 @default.
• W4238514467 hasConcept C143998085 @default.
• W4238514467 hasConcept C182979987 @default.
• W4238514467 hasConcept C2777148230 @default.
• W4238514467 hasConcept C2779138821 @default.
• W4238514467 hasConcept C2779490328 @default.
• W4238514467 hasConcept C2780210213 @default.
• W4238514467 hasConcept C2780259306 @default.
• W4238514467 hasConcept C2781187634 @default.
• W4238514467 hasConcept C501734568 @default.
• W4238514467 hasConcept C502942594 @default.
• W4238514467 hasConcept C526805850 @default.
• W4238514467 hasConcept C54355233 @default.
• W4238514467 hasConcept C71924100 @default.
• W4238514467 hasConcept C82381507 @default.
• W4238514467 hasConcept C86803240 @default.
• W4238514467 hasConceptScore W4238514467C104317684 @default.
• W4238514467 hasConceptScore W4238514467C121608353 @default.
• W4238514467 hasConceptScore W4238514467C126322002 @default.
• W4238514467 hasConceptScore W4238514467C13514818 @default.
• W4238514467 hasConceptScore W4238514467C143998085 @default.
• W4238514467 hasConceptScore W4238514467C182979987 @default.
• W4238514467 hasConceptScore W4238514467C2777148230 @default.
• W4238514467 hasConceptScore W4238514467C2779138821 @default.
• W4238514467 hasConceptScore W4238514467C2779490328 @default.
• W4238514467 hasConceptScore W4238514467C2780210213 @default.
• W4238514467 hasConceptScore W4238514467C2780259306 @default.
• W4238514467 hasConceptScore W4238514467C2781187634 @default.
• W4238514467 hasConceptScore W4238514467C501734568 @default.
• W4238514467 hasConceptScore W4238514467C502942594 @default.
• W4238514467 hasConceptScore W4238514467C526805850 @default.
• W4238514467 hasConceptScore W4238514467C54355233 @default.
• W4238514467 hasConceptScore W4238514467C71924100 @default.
• W4238514467 hasConceptScore W4238514467C82381507 @default.
• W4238514467 hasConceptScore W4238514467C86803240 @default.
• W4238514467 hasIssue "15_suppl" @default.
• W4238514467 hasLocation W42385144671 @default.
• W4238514467 hasOpenAccess W4238514467 @default.
• W4238514467 hasPrimaryLocation W42385144671 @default.
• W4238514467 hasRelatedWork W1217921 @default.
• W4238514467 hasRelatedWork W14450087 @default.
• W4238514467 hasRelatedWork W15367784 @default.
• W4238514467 hasRelatedWork W16703258 @default.
• W4238514467 hasRelatedWork W3580232 @default.

• next